by Plus Therapeutics | Jan 15, 2025 | Uncategorized
Stay Updated with Plus Therapeutics – Follow Us & Subscribe! Want the latest updates on Plus Therapeutics and cutting-edge industry news? Stay informed by following us on all our social media accounts and subscribing to our email newsletter! 🔹 Be the first to know...
by Plus Therapeutics | Jan 2, 2025 | Uncategorized
🎉 Happy New Year from Plus Therapeutics! 🎉 As we ring in the new year, we want to extend our heartfelt gratitude to the patients, medical staff, and the entire cancer community who have supported our mission throughout 2024. Thanks to your dedication and hard work,...
by Plus Therapeutics | Jan 1, 2025 | Uncategorized
ReSPECT Clinical Trials on BrainsFortheCure.org What is Recurrent Glioblastoma (GBM)? Recurrent glioblastoma is a particularly aggressive form of brain cancer that tends to return after initial treatment. GBM recurrence is a major challenge for both patients and...
by Plus Therapeutics | Dec 25, 2024 | Uncategorized
Missed Plus Therapeutics at SNO Annual 2024? Catch Our Latest Presentations Online – Including ReSPECT-LM Phase 1 Interim Data If you weren’t able to attend the SNO Annual Meeting 2024 this year, don’t worry – you can now access all our key presentations online! This...
by Plus Therapeutics | Dec 23, 2024 | Uncategorized
🎄 Happy Holidays from Plus Therapeutics! 🎄 As the end of year year approaches, the Plus Therapeutics team wants to extend our warmest holiday greetings to all of our patients, partners, and supporters. We are taking some time this week to relax and recharge with our...
by Plus Therapeutics | Dec 3, 2024 | Uncategorized
Plus Therapeutics Expands Strategic Partnership with Telix IsoTherapeutics for Rhenium-186 Radioisotope Supply BREAKING NEWS: Plus Therapeutics is pleased to announce the expansion of our strategic agreement with Telix IsoTherapeutics Group, a move that strengthens...
Recent Comments